GB1128005A - Improvements in or relating to antigenic and allergenic preparations - Google Patents
Improvements in or relating to antigenic and allergenic preparationsInfo
- Publication number
- GB1128005A GB1128005A GB14683/66A GB1468366A GB1128005A GB 1128005 A GB1128005 A GB 1128005A GB 14683/66 A GB14683/66 A GB 14683/66A GB 1468366 A GB1468366 A GB 1468366A GB 1128005 A GB1128005 A GB 1128005A
- Authority
- GB
- United Kingdom
- Prior art keywords
- antigenic
- substance
- allergenic
- preparations
- allergenic preparations
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 230000002009 allergenic effect Effects 0.000 title abstract 3
- 230000000890 antigenic effect Effects 0.000 title abstract 3
- 238000002360 preparation method Methods 0.000 title abstract 3
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 abstract 3
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical class OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 abstract 2
- 239000000126 substance Substances 0.000 abstract 2
- UMGDCJDMYOKAJW-UHFFFAOYSA-N thiourea Chemical compound NC(N)=S UMGDCJDMYOKAJW-UHFFFAOYSA-N 0.000 abstract 2
- 241000186046 Actinomyces Species 0.000 abstract 1
- 239000004215 Carbon black (E152) Substances 0.000 abstract 1
- 102000002322 Egg Proteins Human genes 0.000 abstract 1
- 108010000912 Egg Proteins Proteins 0.000 abstract 1
- 241000186359 Mycobacterium Species 0.000 abstract 1
- 241000186367 Mycobacterium avium Species 0.000 abstract 1
- 241000186365 Mycobacterium fortuitum Species 0.000 abstract 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 abstract 1
- 241000193996 Streptococcus pyogenes Species 0.000 abstract 1
- 239000011149 active material Substances 0.000 abstract 1
- 239000013566 allergen Substances 0.000 abstract 1
- 229960003116 amyl nitrite Drugs 0.000 abstract 1
- 239000000427 antigen Substances 0.000 abstract 1
- 102000036639 antigens Human genes 0.000 abstract 1
- 108091007433 antigens Proteins 0.000 abstract 1
- 230000001580 bacterial effect Effects 0.000 abstract 1
- 239000004202 carbamide Substances 0.000 abstract 1
- 239000006185 dispersion Substances 0.000 abstract 1
- 230000002708 enhancing effect Effects 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 230000002538 fungal effect Effects 0.000 abstract 1
- 229960003711 glyceryl trinitrate Drugs 0.000 abstract 1
- 229930195733 hydrocarbon Natural products 0.000 abstract 1
- 150000002430 hydrocarbons Chemical class 0.000 abstract 1
- 230000003053 immunization Effects 0.000 abstract 1
- CSDTZUBPSYWZDX-UHFFFAOYSA-N n-pentyl nitrite Chemical compound CCCCCON=O CSDTZUBPSYWZDX-UHFFFAOYSA-N 0.000 abstract 1
- 229960003512 nicotinic acid Drugs 0.000 abstract 1
- 235000001968 nicotinic acid Nutrition 0.000 abstract 1
- 239000011664 nicotinic acid Substances 0.000 abstract 1
- 230000035515 penetration Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- JIVZKJJQOZQXQB-UHFFFAOYSA-N tolazoline Chemical class C=1C=CC=CC=1CC1=NCCN1 JIVZKJJQOZQXQB-UHFFFAOYSA-N 0.000 abstract 1
- 229960002485 trolnitrate Drugs 0.000 abstract 1
- HWKQNAWCHQMZHK-UHFFFAOYSA-N trolnitrate Chemical compound [O-][N+](=O)OCCN(CCO[N+]([O-])=O)CCO[N+]([O-])=O HWKQNAWCHQMZHK-UHFFFAOYSA-N 0.000 abstract 1
- 229960001005 tuberculin Drugs 0.000 abstract 1
- 241000712461 unidentified influenza virus Species 0.000 abstract 1
- 230000003612 virological effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/531—Production of immunochemical test materials
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
Abstract
1,128,005. Antigenic and allergenic preparations. MEDIMPEX GYOGYSZERKULKERESKEDELMI VALLALAT. 1 April, 1966, No. 14683/66. Heading A5B. Antigenic and allergenic preparations for percutaneous application for immunizing, diagnosing or testing are prepared by forming a homogenous dispersion of water, a lipoid or liphophilic substance, e.g. a fat or oil or hydrocarbon containing at least 8 C. atoms, urea and/or thiourea and an allergen or a bacterial, fungal or viral antigen. Specified active materials are killed streptococcus haemolyticus; mycobacterium typus humanus; M. avium; M. minetti; egg protein; tuberculin; influenza virus and streptothrix actinomyces. A substance enhancing penetration into the skin, e.g. amyl nitrite, nitroglycerine, triethanolamine trinitrate, esters or salts of nicotinic acid or 2-benzyl-4, 5-imidazoline may be included.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB14683/66A GB1128005A (en) | 1966-04-01 | 1966-04-01 | Improvements in or relating to antigenic and allergenic preparations |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB14683/66A GB1128005A (en) | 1966-04-01 | 1966-04-01 | Improvements in or relating to antigenic and allergenic preparations |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| GB1128005A true GB1128005A (en) | 1968-09-25 |
Family
ID=10045699
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| GB14683/66A Expired GB1128005A (en) | 1966-04-01 | 1966-04-01 | Improvements in or relating to antigenic and allergenic preparations |
Country Status (1)
| Country | Link |
|---|---|
| GB (1) | GB1128005A (en) |
Cited By (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4340586A (en) * | 1977-02-18 | 1982-07-20 | Adam Bekierkunst | Pharmaceutical preparation for treating disorders of the skin |
| WO2003080792A2 (en) * | 2002-03-22 | 2003-10-02 | Hans Wolf | Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment |
| US9476878B2 (en) | 2009-04-09 | 2016-10-25 | Lophius Biosciences Gmbh | Method for the detection of polypeptide specific immune cells |
-
1966
- 1966-04-01 GB GB14683/66A patent/GB1128005A/en not_active Expired
Cited By (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4340586A (en) * | 1977-02-18 | 1982-07-20 | Adam Bekierkunst | Pharmaceutical preparation for treating disorders of the skin |
| WO2003080792A2 (en) * | 2002-03-22 | 2003-10-02 | Hans Wolf | Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment |
| WO2003080792A3 (en) * | 2002-03-22 | 2004-01-22 | Hans Wolf | Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment |
| DE10212867B4 (en) * | 2002-03-22 | 2005-07-21 | Hans Prof. Dr. Wolf | Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and therapy |
| US7829331B2 (en) | 2002-03-22 | 2010-11-09 | Hans Wolf | Use of urea-adjuvated polypeptides for diagnosis, prophylaxis and treatment |
| US9476878B2 (en) | 2009-04-09 | 2016-10-25 | Lophius Biosciences Gmbh | Method for the detection of polypeptide specific immune cells |
| US9850464B2 (en) | 2009-04-09 | 2017-12-26 | Lophius Biosciences Gmbh | Method for the detection of polypeptide specific immune cells |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| GB1451669A (en) | Protein staining | |
| GB1128005A (en) | Improvements in or relating to antigenic and allergenic preparations | |
| Pickford | Induction of a spawning reflex in hypophysectomized killifish | |
| Phelps | A Note on the Non-Specific Action of So-Called “Anti-Cancer Serum” | |
| NL172857C (en) | METHOD FOR PREPARING PREPARATIONS WITH INSECTICIDE AND ACARICIDE ACTION, AND METHOD FOR PREPARING ESTERS OF N- (DIMETHYLAMINOMETHYLIDEOSHYLOROSHOROSHOROSHOROSHOROSHOROSHOROSHOROSHOSPHOROSHOSPHOROSHOROSHOROSHOROSPHOSHOROSHOROSPHOROSHOROSPHOROSHIPHOSPHOSPHYLOSHITOSPHEREUS PREPARATORY PREPARATIONS) | |
| GB1192576A (en) | Diagnostic Substance and Composition | |
| Ajjan et al. | Intradermal immunization with rabies vaccine: inactivated Wistar strain cultivated in human diploid cells | |
| NL176425B (en) | PROCESS FOR PREPARING PREPARATIONS WITH PESTICIDE ACTION, WHICH CONTAINS AS ACTIVE SUBSTANCE S.S-DIPROPYL-O-ETHYL PHOSPHORDITHIOATE AND / OR S.S-DIETHYL-O-ETHYL PHOSPHORDITHIOITE. | |
| GB1274291A (en) | Counteracting harmful micri-organisms in a substrate with microbial commensals and other agents | |
| Kato et al. | Suppression of BCG cell wall induced delayed-type hypersensitivity by BCG pre-treatment. I. Induction of adherent suppressor cells by live BCG injection and their characterization. | |
| Kamei et al. | Production of phage-neutralizing activity in vitro by cells derived from Burkitt's lymphoma | |
| Dunkin | The Preparation of Johnin from a Synthetic Medium without the addition of B. phlei | |
| Nagy | Induction of autohemolysin formation in spleen cell culture by “immunogenic RNA” | |
| Wong et al. | Further Studies on Type-Specific Protein of Corynebacterium diphtheriae. | |
| Koerber et al. | Use of mice in testing of antigenic power of tetanus toxoid | |
| Chaparas et al. | Tuberculin sensitivity and precipitins induced by soluble antigens from Mycobacterium bovis (BCG) culture filtrate incorporated in Freund's adjuvant containing Nocardia asteroides | |
| Sigurdsson et al. | Immunization with heat-killed Mycobacterium paratuberculosis in mineral oil. II | |
| DE814315C (en) | Process for the production of serums, vaccines and the like like | |
| Oppenheim et al. | IMMUNE STATUS OF MICE TOLERANT OF LIVING CELLS: III. PRESENCE AND EVOLUTION OF CELLS CYTOTOXIC TO THE TOLERATED STRAIN | |
| Larson et al. | Comparison of antigenic fractions obtained by Seibert and Affronti method from protoplasm and culture filtrates of Mycobacterium bovis (BCG) | |
| Skoog et al. | Interaction between antilymphocyte globulin and phytohemagglutinin in human lymphocyte cultures | |
| NL174111B (en) | METHOD FOR THE PREPARATION OF INSECTICIDE PREPARATIONS. | |
| Hooser et al. | Elimination of pleuropneumonia-like organisms from embryonic human lung tissue culture with tetracycline | |
| Korosteleva et al. | The antigenic structure of the normal spleen | |
| Sherwood et al. | Discrepancy in analysis of penicillin in blood by the Oxford cup method as revealed by the paper disc technique |